Key Points
- Insider sale: ICU Medical VP Virginia Sanzone sold 4,856 shares for approximately $819,159 under a pre-arranged Rule 10b5-1 trading plan, reducing her position by 24.95% to 14,604 shares.
- Quarterly performance: ICU Medical reported adjusted earnings of $2.37 per share, exceeding the $1.91 analyst consensus, while revenue of $547.88 million also topped estimates. The company reaffirmed fiscal 2026 EPS guidance of $8.60–$9.00.
- Market outlook: Shares opened at $166.29, while analysts maintain a “Moderate Buy” consensus and an average price target of $192.80. Institutional investors own 96.10% of the stock.
ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) VP Virginia Sanzone sold 4,856 shares of the stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $168.69, for a total transaction of $819,158.64. Following the transaction, the vice president owned 14,604 shares of the company's stock, valued at $2,463,548.76. This trade represents a 24.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
ICU Medical Stock Performance
ICU Medical stock opened at $166.29 on Friday. The company's 50-day moving average price is $166.96 and its 200-day moving average price is $144.70. ICU Medical, Inc. has a twelve month low of $112.50 and a twelve month high of $192.85. The company has a quick ratio of 1.21, a current ratio of 2.43 and a debt-to-equity ratio of 0.56. The company has a market cap of $4.16 billion, a PE ratio of 140.92, a price-to-earnings-growth ratio of 2.15 and a beta of 0.75.
ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, beating analysts' consensus estimates of $1.91 by $0.46. The firm had revenue of $547.88 million during the quarter, compared to the consensus estimate of $533.44 million. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The firm's revenue for the quarter was up .5% compared to the same quarter last year. During the same quarter last year, the firm earned $2.10 EPS. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, equities research analysts forecast that ICU Medical, Inc. will post 7.19 EPS for the current fiscal year.
Institutional Investors Weigh In On ICU Medical
Several hedge funds have recently made changes to their positions in ICUI. California State Teachers Retirement System grew its position in shares of ICU Medical by 14,236.6% during the 2nd quarter. California State Teachers Retirement System now owns 3,944,273 shares of the medical instruments supplier's stock worth $578,230,000 after buying an additional 3,916,761 shares in the last quarter. BlackRock Inc. bought a new stake in shares of ICU Medical in the second quarter valued at about $550,250,000. Jupiter Topco LLC bought a new stake in shares of ICU Medical in the second quarter valued at about $407,786,000. Vanguard Group Inc. lifted its stake in ICU Medical by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 2,714,746 shares of the medical instruments supplier's stock worth $387,313,000 after acquiring an additional 89,755 shares during the period. Finally, Janus Henderson Group PLC lifted its stake in ICU Medical by 3.9% in the first quarter. Janus Henderson Group PLC now owns 2,676,012 shares of the medical instruments supplier's stock worth $345,607,000 after acquiring an additional 99,256 shares during the period. 96.10% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
ICUI has been the subject of several analyst reports. Needham & Company LLC raised their price objective on ICU Medical from $165.00 to $187.00 and gave the company a "buy" rating in a research note on Friday, August 7th. KeyCorp increased their price target on ICU Medical from $164.00 to $182.00 and gave the company an "overweight" rating in a report on Tuesday, July 21st. Jefferies Financial Group upgraded ICU Medical to a "strong-buy" rating in a report on Thursday, May 7th. Wall Street Zen upgraded ICU Medical from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 8th. Finally, Zacks Research lowered shares of ICU Medical from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $192.80.
View Our Latest Stock Analysis on ICUI
ICU Medical Company Profile
(
Get Free Report)
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
